The Italian pharmaceutical market environment, from regulatory to regulatory, has always been a highly changeable scenario, both because of continuous technological advances and because of regulations that adapt to innovation and chase urgencies.
We live in interesting times, we are experiencing an epoch-making moment, the SARS-CoV-2 pandemic; in Italy, all stakeholders are working - some planning, some lobbying with proposals - on a new drug governance. With this infographic, we have tried to imagine the future scenario of market access in these interesting times.

Single National Ethics Committee of the Lazzaro Spallanzani National Institute for Infectious Diseases
Article 17 of the Cura Italia decree-law states that the national opinion on protocols for the testing of medicines for epidemiological emergencies by COVID is provided, limited to

